Evidence map›Paper›PMID 35526514›Full record

ArticleNeurobiology of aging2022

Cognitive resilience to three dementia-related neuropathologies in an oldest-old man: A case report from The 90+ Study.

Zarui A Melikyan, María M Corrada, Anne-Marie Leiby, Seyed Ahmad Sajjadi, Syed Bukhari, Thomas J Montine, Claudia H Kawas

Open access · bronzeAbstract readCase Reports
In one paragraph

Article in Neurobiology of aging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Zarui A MelikyanInstitute for Memory Impairments and Neurologic Disorders, University of California, Irvine, CA, USA. Electronic address: zmelikya@uci.edu.
María M CorradaInstitute for Memory Impairments and Neurologic Disorders, University of California, Irvine, CA, USA; Department of Neurology, University of California, Irvine, CA, USA; Department of Epidemiology, University of California, Irvine, CA, USA.
Anne-Marie LeibyDepartment of Neurology, University of California, Irvine, CA, USA.
Seyed Ahmad SajjadiInstitute for Memory Impairments and Neurologic Disorders, University of California, Irvine, CA, USA; Department of Neurology, University of California, Irvine, CA, USA.
Syed BukhariDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Thomas J MontineDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Claudia H KawasInstitute for Memory Impairments and Neurologic Disorders, University of California, Irvine, CA, USA; Department of Neurology, University of California, Irvine, CA, USA; Department of Neurobiology and Behavior, University of California, Irvine, CA, USA.
University of California, Irvine · USStanford University · US

Funding

Diversity Supplement to R01AG021055; Clinical, Imaging, and Pathological Studies in the Oldest Old: The 90+ StudyR01AG021055 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI CORRADA, MARIA, KAWAS, CLAUDIA H. · 2002 to 2024
$36.9M
The Alzheimer's Disease Research Center at the University of California, IrvineP30AG066519 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI Elizabeth Head · 2020 to 2026
$27.9M
Diagnosis and Risk factors of hippocampal sclerosis of aging and limbic predominant age related TDP-43 encephalopathy; common Alzheimer’s mimicsR01AG062706 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI Seyed Ahmad Sajjadi · 2019 to 2026
$9.2M
Neuropathologic substrates for motor and cognitive impairment in three existing cohort studies of Alzheimer's disease and related dementiasUF1AG057707 · NIA · STANFORD UNIVERSITY · PI MONTINE, THOMAS J, WHITE, LON RAY · 2017 to 2017
$3.9M
NIA NIH HHS P30 AG066519NIA NIH HHS R01 AG021055NIA NIH HHS UF1 AG057707
6 · The paper itself

Abstract

Cognitive resilience provides insights into maintaining good cognition despite dementia-related neuropathologic changes. It is of special interest in the oldest-old (age 90+) because age is the strongest risk factor for dementia. We describe the only participant of The 90+ Study, among 367 autopsies, who maintained normal cognition despite intermediate-high levels of 3 dementia-related neuropathologic changes, advanced age, and comorbidities associated with cognitive impairment. This man remained cognitively normal throughout 13 semi-annual study visits, last one being 4 months before his death at 96. His cognitive test scores remained around the 90th percentile for non-timed tests and declined from 90th to 50th percentile (significant for semantic fluency) for timed tests. He remained physically and cognitively active until death, despite extrapyramidal signs in the last year of life. Neuropathological examination revealed intermediate level of Alzheimer's disease neuropathologic change (Thal phase 5, Braak NFT stage IV, CERAD score 3), Lewy bodies and neurites in the olfactory bulb, brainstem and limbic areas (Braak PD stage 4), TDP-43 inclusions in the amygdala and hippocampus (LATE stage 2), and a microvascular lesion in putamen. This case demonstrates that cognitive impairment is not inevitable even in the oldest-old with mutltiple dementia-related neuropathologic changes.

Indexed as

Alzheimer DiseaseCognitive DysfunctionAged, 80 and overCognitionHumansLewy BodiesMaleNeuropsychological TestsAge 90+Cognitive resilienceNeuropathologyOldest-old

Identifiers

PMID35526514
PMCPMC9733494
OpenAlexW4221106394

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.